Effect of Pulmonary Rehabilitation in Females With Acute Exacerbation of COPD Induced by Biomass … (NCT07509736) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Effect of Pulmonary Rehabilitation in Females With Acute Exacerbation of COPD Induced by Biomass Fuel Smoke
60 participantsStarted 2026-03-20
Plain-language summary
COPD represents an important public health challenge that is both preventable and treatable. GOLD is committed to improving the health of people at risk of and with COPD, wherever they happen to have been born, and wishes to do its bit to help achieve the United Nations Sustainable Development Goal to reduce premature mortality from non-communicable diseases - including COPD - by one third by 2030. GOLD aims in stable COPD to relieve symptoms, improve exercise tolerance and improve health status. Non-pharmacological interventions for those high-risk groups of patients, studies of intervention strategies both during inpatient stay and shortly after discharge have been undertaken, to decrease readmission rates and improve QOL, including disease-specific self-management, pulmonary rehabilitation, and early medical follow-up.Seeking for allow cost way to alleviate patients' symptoms in order to increase independence and QOL.
Who can participate
Age range
50 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Only females diagnosed with a history of using biomass fuel for cooking and heating during their lifetime with no history of smoking or being Ex smoker nor a non-smoker.
* Participants in clear consciousness.
* participants diagnosed with shortness of breath or dyspnea that was not caused by heart disease, pneumothorax, or pulmonary oedema
Exclusion Criteria:
* Systolic blood pressure lower than 90 mmHg.
* Participants with unstable psychological status, hemoptysis, pneumothorax, pulmonary edema.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Exercise tolerance
Timeframe: 2 months (8 weeks)
Trial details
NCT IDNCT07509736
SponsorBeni-Suef University
Sponsor typeOTHER
Study typeINTERVENTIONAL
Primary completion2026-06-10
Contact for this trial
Marwa Mohammed Mohammed Eleawa, Assistant professor